A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gottfried E. Konecny,Amit M. Oza,Anna V. Tinker,Ana Oaknin,Ronnie Shapira-Frommer,Isabelle Ray-Coquard,Carol Aghajanian,Robert L. Coleman,David M. O'Malley,Alexandra Leary,Lee-may Chen,Diane Provencher,Ling Ma,James D. Brenton,Cesar M. Castro,Michelle Green,Andrew Simmons,Jeri Beltman,Thomas Harding,Kevin K. Lin,Sandra Goble,Lara Maloney,Rebecca Kristeleit,Iain A. McNeish,Elizabeth M. Swisher,Jim J. Xiao +25 more
TL;DR: In this paper, the authors evaluated correlations between rucaparib exposure and selected efficacy and safety endpoints in patients with recurrent ovarian carcinoma using pooled data from Study 10 and ARIEL2.
Journal Article
ENGOT-OV16/NOVA: A Maintenance sturdy with Niraparib versus placebo in patients with platinum-sensitive ovarian cancer
Ursula A. Matulonis,Jørn Herrstedt,Amit M. Oza,Sven Mahner,Andrés Redondo,Michel Fabbro,Jonathan A. Ledermann,Domenica Lorusso,Ignace Vergote,O. Rosengarten,Alexander Reinthaller,Radoslaw Madry,Bradley J. Monk,Anne Dørum,Anna V. Tinker,Andreas duBois,A. Gonzalez Martin,Philippe Follana,Jonathan S. Berek,Lawrence E. Gilbert,Benedict B. Benigno,Per Rosenberg,Bobbie J. Rimel,Joseph Buscema,John Balser,Shefali Agarwal,Mansoor Raza Mirza +26 more
Journal ArticleDOI
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
TL;DR: This study will test the hypothesis that ceralasertib + olaparib, or olapARib monotherapy, is tolerable, and effective at prolonging progression-free survival compared with placebo, as second maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma: The effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp,Domenica Lorusso,Amit M. Oza,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Giovanni Scambia,Alexandra Leary,Robert W. Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Susana Banerjee,Jesús García-Donas,Elizabeth M. Swisher,Terri Cameron,Sandra Goble,Robert L. Coleman,Jonathan A. Ledermann +23 more
TL;DR: In this article, the poly(adenosine diphosphate-ribose) polymerase inhibitor rucaparib significantly improved progression-free survival versus placebo regardless of biomarker status when used as maintenance treatment for recurrent ovarian cancer.
Journal ArticleDOI
Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Soyoun Rachel Kim,Soyoun Rachel Kim,Alicia A. Tone,Raymond H. Kim,Raymond H. Kim,Raymond H. Kim,Matthew Cesari,Blaise A. Clarke,Lua Eiriksson,Tae L. Hart,Tae L. Hart,Melyssa Aronson,Spring Holter,Alice Lytwyn,Katherine Lajkosz,Leslie Oldfield,Steven Gallinger,Marcus Q. Bernardini,Marcus Q. Bernardini,Amit M. Oza,Bojana Djordjevic,Jordan Lerner-Ellis,Jordan Lerner-Ellis,Emily Van de Laar,Danielle Vicus,Danielle Vicus,Trevor J. Pugh,Trevor J. Pugh,Aaron Pollett,Aaron Pollett,Sarah E. Ferguson,Sarah E. Ferguson,Sarah E. Ferguson +32 more
TL;DR: In this paper, the impact of mismatch repair deficiency (MMRd) on patient outcomes in endometrial cancer (EC) have been inconsistent to date, finding that MMRd tumors tended to be grade 2 or 3 (56% vs. 29% of MMRd cases).